Archive for ‘Vaccines’

Human Insulin Market Poised to Hit US$ 49,197.3 Million by 2020

Human Insulin Market Poised to Hit US$ 49,197.3 Million by 2020

Insulin-Pen-5

 

Globally, the human insulin market is witnessing significant growth due to increasing prevalence of diabetes and increasing awareness among people about diabetes care. In addition, technological advancements in insulin delivery devices and increasing prevalence of lifestyle related disorders such as obesity are also driving the growth of the market. However, uneven pricing and limited access to human insulin in emerging countries such as Brazil, India, and China are inhibiting the growth of the human insulin market. In addition, strict regulatory requirements for drug approval are also restraining the growth of the market.

The global human insulin market was valued at USD 24,332.6 million in 2014 and was expected to grow at a CAGR of 12.4% from 2014 to 2020, to reach an estimated value of USD 49,197.3 million in 2020.

In addition, increasing prevalence of lifestyle associated disorders such as obesity is also boosting the growth of the human insulin market in this region. For instance, according to the Centers for Diseases Control and Prevention (CDC), a U.S.-based national public health institute, over one-third children and adolescents were obese in 2012 in the U.S.

In North America, increasing prevalence of diabetes with growing age and availability of advanced human insulin infusion devices are driving the use of human insulin in the market.

Request to view Table of Content @ http://www.persistencemarketresearch.com/market-research/human-insulin-market/toc

In Europe, the human insulin market is driven by rising aging population and increasing prevalence of diabetes. In addition, in Germany the market is evolving due to rising prevalence of diabetes and increasing awareness among people about diabetes care. However, in Asia-Pacific the growth for human insulin is much higher than developed countries due to increasing prevalence of diabetes and increasing government initiatives for improving healthcare.

To Purchase Single User License @ http://www.persistencemarketresearch.com/checkout/3308

Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., Adocia, Merck & Co., Inc., Pfizer, Inc., Wockhardt, Julphar, Bristol-Myers Squibb Company, GlaxoSmithKline Plc and Oramed Pharmaceuticals, Inc. are some of the major players in human insulin market.

About Us

Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States

USA – Canada Toll Free: +1 800-961-0353

Email: sales@persistencemarketresearch.com

media@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Full story

New system can predict timing and severity of seasonal influenza outbreaks

New system can predict timing and severity of seasonal influenza outbreaks

Scientists have developed a system to predict the timing and severity of seasonal influenza outbreaks that could one day help health officials and the general public better prepare for them. The system adapts techniques used in modern weather prediction to turn real-time, Web-based estimates of influenza infection into local forecasts of seasonal flu.

Results appear online in the Proceedings of the National Academy of Sciences.

Year to year, and region to region, there is huge variability in the peak of flu season, which, in temperate areas of the Northern Hemisphere, can happen as early as October or as late as April. The forecast system can provide “a window into what can happen week to week as flu prevalence rises and falls,” says Jeffrey Shaman, PhD, an assistant professor of Environmental Health Sciences at Columbia University’s Mailman School of Public Health.

As a test case, Dr. Shaman and Alicia Karspeck, PhD, of the National Center for Atmospheric Research, used Web-based estimates of flu-related sickness from the 2003-2008 influenza seasons in New York City to retrospectively generate weekly flu forecasts and found that the technique could predict the peak timing of the outbreak more than seven weeks in advance of the actual peak.

In the future, such flu forecasts might conceivably be disseminated on the local television news along with the weather report, says Dr. Shaman. Like the weather, flu conditions vary from region to region; Atlanta might peak weeks ahead of Anchorage. “Because we are all familiar with weather broadcasts, when we hear that there is a 80% chance of rain, we all have an intuitive sense of whether or not we should carry an umbrella,” says Dr. Shaman. “I expect we will develop a similar comfort level and confidence in flu forecasts and develop an intuition of what we should do to protect ourselves in response to different forecast outcomes.”

As individuals, a flu forecast could prompt us to get a vaccine, exercise care around people sneezing and coughing, and better tune in to how we feel. For health officials, it could inform decisions on how many vaccines and antiviral drugs to stockpile, and in the case of a virulent outbreak, whether other measures, like closing schools, is necessary.

“Flu forecasting has the potential to significantly improve our ability to prepare for and manage the seasonal flu outbreaks that strike each year,” says Irene Eckstrand, PhD, of the National Institutes of Health’s National Institute of General Medical Sciences, which provided funding for the study.

Worldwide, influenza kills an estimated 250,000 to 500,000 people each year; in the U.S. about 35,000 die from the flu every year.

The seed of the new study was planted four years ago in a conversation between the two researchers, in which Dr. Shaman expressed an interest in using models to forecast influenza. Dr. Karspeck “recommended incorporating some of the data assimilation techniques used in weather forecasting to build a skillful prediction system” remembers Dr. Shaman.

In weather forecasting real-time observational data are used to “nudge the model to conform with reality and reduce error in the model simulations,” he explains. Applying this method to flu forecasting, the researchers used near-real-time data from Google Flu Trends, which estimates outbreaks based on the number of flu-related search queries in a given region.

Going forward, Dr. Shaman will test the model in other localities across the country using up-to-date data. This is necessary, he says, since “there is no guarantee that just because the method works in New York it will work in Miami.”

Source : http://www.news-medical.net/news/20121127/New-system-can-predict-timing-and-severity-of-seasonal-influenza-outbreaks.aspx

Full story

GORE Hybrid Vascular Graft receives CE Mark approval

GORE Hybrid Vascular Graft receives CE Mark approval

W. L. Gore & Associates (Gore) has received CE Mark for the GORE® Hybrid Vascular Graft. The graft is designed to expand treatment options for optimal outflow by maximizing the number of access sites available. Twelve month follow-up data for newly created access implants demonstrates a trend towards significant improvement in functional graft patency and reduction in seroma, as compared to historical graft data. Since commercialization, there have been more than 2500 successful implants of the GORE Hybrid Vascular Graft in patients suffering occlusive or aneurysmal diseases, in trauma patients requiring vascular replacement, for dialysis access, and other vascular procedures.

The GORE Hybrid Vascular Graft, which received FDA clearance in 2010, is indicated for use as a vascular prosthesis for replacement or bypass of diseased vessels impacted by aortic aneurysmal, peripheral vascular and end stage renal disease. The device is designed to address the most common causes of graft failure; intimal hyperplasia, thrombosis, and seroma. The device simplifies access to vessels with an optional over the wire deployment method that reduces vessel injury and dissection. The GORE Hybrid Vascular Graft has been used to create new access sites in anatomical locations that would have otherwise been abandoned, preserving the amount of access sites available throughout the patient’s long-term therapy.

“The GORE Hybrid Vascular Graft, for the first time, palpably bridges the gap between traditional vascular and endovascular surgery. It is the first significant innovation in vascular grafts in years, providing tremendous versatility,” said Jean Bismuth, MD, Assistant Professor at the Methodist DeBakey Heart and Vascular Center in Houston, Texas. “The GORE Hybrid Vascular Graft allows the surgeon to create a sutureless anastomosis and displays significant potential for improving hemodynamics.”

The GORE Hybrid Vascular Graft combines several trusted Gore technologies. The expanded polytetrafluoroethylene (ePTFE) vascular prosthesis has a section reinforced with nitinol. The nitinol reinforced section is partially constrained to allow for easy insertion and deployment into vessels that are difficult to reach or in challenging anatomical locations. It is the only combination graft of its kind that incorporates CARMEDA® BioActive Surface (CBAS® Surface) with covalently bonded heparin, resulting in a proven thromboresistant surface.

“Receiving CE Mark for the GORE Hybrid Vascular Graft demonstrates our commitment to providing physicians with innovative technology that can expand treatment options and improve patient outcomes worldwide,” said Chuck Biggerstaff, associate with the Gore Venous Access Business.

Source : http://www.news-medical.net/news/20120820/GORE-Hybrid-Vascular-Graft-receives-CE-Mark-approval.aspx

Full story

Disposable Insulin Delivery Device Got FDA Clearance

Disposable Insulin Delivery Device Got FDA Clearance

The V-Go Disposable Insulin Delivery Device has received 510(k) clearance from the U.S. Food and Drug Administration.

The V-Go is for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin. V-Go devices will be available in a preset basal rate to deliver 20, 30, or 40 Units of insulin in one 24-hour period (0.83 U/hr, 1.25 U/hr or 1.67 U/hr, respectively) and on-demand bolus dosing in 2 Unit increments (up to 36 Units per one 24-hour time period). The V-Go offers a simple way to deliver basal-bolus therapy.

The V-Go is the first simple, fully disposable device for the delivery of basal-bolus insulin therapy for adults with diabetes. The V-Go provides a continuous preset basal rate of insulin and allows for on-demand bolus dosing around mealtimes thereby providing an alternative to taking multiple daily insulin injections.

The V-Go is engineered to simplify basal-bolus insulin therapy for the millions of people suffering from Type 2 diabetes. The V-Go is small, lightweight, and worn under the patients clothing. It measures just 2.4 x 1.3 x 0.5 inches and weighs approximately 1 ounce when filled with insulin. Patients apply a new V-Go to the skin daily for one 24-hour period. The V-Go is not electronic, making it easy to operate and use.

About Diabetes

Diabetes is a chronic and progressive disease in which the body fails to produce or properly utilize insulin, a hormone that regulates blood sugar (glucose) levels.1 High blood glucose levels can lead to serious complications, including heart disease, stroke, high blood pressure, blindness, kidney disease, amputation, and even premature death.2

Approximately 23.6 million US children and adults have diabetes, including nearly 6 million who are undiagnosed.2 Diabetes is classified as Type 1 or Type 2. The Type 2 form of the disease is most common, affecting approximately 95% of adults with diabetes.1 In Type 2 diabetes, either the body does not produce enough insulin or the body’s cells do not use insulin properly.1 In Type 1 diabetes, the body stops producing insulin altogether.1,3

To control blood glucose levels, approximately 4.5 million people in the US with Type 2 diabetes take insulin4, which is usually administered by injection. About 3 million of these insulin users have not achieved target glucose levels currently recommended by the American Diabetes Association.4,5 In addition, many people with Type 2 diabetes could benefit from insulin therapy, but refuse to start on therapy or skip taking insulin for a variety of reasons, including interference with daily activities, injection pain, and embarrassment about injecting medication around family and friends or in public.6,7 In one study, approximately 80% of Type 2 diabetes patients only required a single daily basal rate of insulin.8 Using continuous subcutaneous insulin infusion therapy for Type 2 diabetes mellitus patients may lead to improved glycemic control.

Link

Related Posts Plugin for WordPress, Blogger...

Full story

Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes